A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum
Completed · Phase 2 · NCT05569252
Conditions: Pseudoxanthoma Elasticum
At a glance
- Research payments reported, 2025
- $72
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 65
About the trial
- Sponsor
- Daiichi Sankyo (with PXE International)
- Tested
- DS-1211b (drug), Placebo (other)
- Dates
- Started 2022-10-20; completion 2023-11-21
- Results posted
- Yes
This study was designed to evaluate the safety, tolerability, pharmacodynamics (PD) of DS-1211b, and pharmacokinetics (PK) in individuals with Pseudoxanthoma elasticum (PXE). PXE is a rare disease that is associated with significant risks of visual impairments and comorbidity from peripheral and cardiovascular diseases, and adversely impacts the quality of life in afflicted individuals.
From ClinicalTrials.gov, last updated 2024-12-31. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $72 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Frontage Laboratories Inc $72
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.